Vaccine initiative money reallocated; emphasis placed on research and mother-to-child transmission.

Abstract

When the federal government officially announced in February 2010 the cancellation of a CAN dollars 88 million project to establish a pilot-scale HIV vaccine manufacturing facility in Canada, it was unclear how the money would finally be used. However, in July the announcement came that the funds would be reallocated to research and to the prevention of mother-to-child transmission of HIV.